Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., March 06, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the fourth quarter and year ended December 31, 2024, and provided a business update. “Based on our significant progress in 2024, we are now positioned to announce…

BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE’s management will participate in two investor conferences in March. Details are as follows: TD Cowen 45th Annual Health Care Conference, Boston, MA Conference Date:   March 4, 2025 Format:   Fireside chat and one-on-one meetings Fireside Chat Timing:   Tuesday, March 4, 2025, 11:10 AM ET Registration:    Webcast link       Leerink Partners Global Healthcare Conference, Miami,…